India's Piramal Pharma up after US FDA ends inspection at facility
15/07/2024 05:21
** Shares of Piramal Pharma PIRM.NS rise 2.3% to 154.53
rupees, set for best day in about a month
** Co says U.S. FDA completes inspection of Ahmedabad
facility with Zero Form - 483 observations - and 'no action
indicated' designation
** PIRM set to snap three-day losing streak
** Stock up ~11% YTD
(Reporting by Dimpal Gulwani in Bengaluru)
((dimpal.gulwani@thomsonreuters.com))
Recent news on Piramal Pharma (Mumbai)
See all newsBrief: Piramal Pharma (Mumbai) Says Commercial Arrangement With Bayer Pharmaceuticals To Expire On December 31, 2026
Brief: Piramal Pharma (Mumbai) Says Tax Authority Confirms Demand Of 40.6 Million Rupees And Imposes Equivalent Penalty
India's Piramal Pharma falls after US FDA observations at UK facility
Brief: Piramal Pharma Says US FDA Issues Form-483 With 7 Observations To Morpeth UK Facility
Brief: Piramal Pharma Approves Exercise Of Call Option For Acquisition Of Additional 41% Equity In Yapan Bio